XZXiao Zheng

Xiao Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiao Zheng has a total of 178 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diet-microbiome interaction shapes stress susceptibility via a gut-brain neurometabolic circuit

    by Youying Zhang, Ruizhe Nie, Zixin Chen, Xuanyao Li, Zemin Li, Yuanlong Hou, Chunyu Li, Guangbo Kang, Ying Shan, Yunqian Xu, et al.

  • GPR35 in host–microbe interaction: Mechanisms and translational prospects

    by Jian Chen, Xiaoying Cai, Qingyun Ma, Haiping Hao, Xiao Zheng

  • Ketogenic Diet Modulates Depressive‐Like Behavior via Gut Bacterial Metabolism of Tyrosine

    by Youying Zhang, Xuanyao Li, Xuanshuang Zhang, Ying Wang, Zixin Chen, Xuan Lin, Xiao Zheng, Haiping Hao, Xueli Zhang

    Emerging evidence suggests the therapeutic potential of ketogenic diet (KD) for mood disorders such as depression, yet the underlying mechanisms are poorly understood. Here we report a gut microbe‐to‐brain signaling pathway through which KD protects against depressive‐like behavior in mice. We show that KD feeding triggers a prompt and dynamic remodeling of the gut microbiome, the depletion of which abrogates the protective effect of KD against depressive‐like behavior in stressed mice. Colonization with Roseburia intestinalis ( R. intestinalis ), which is enriched by 1‐week KD, sustains the protective effect of KD against depressive‐like behavior in mice. The protective effect of KD is linked to the reduction of a host‐microbe co‐metabolite p‐Cresol sulfate (p‐CS), the supplementation of which negates the protective effect of KD against depressive‐like behavior. Mechanistically, p‐CS enters the brain and activates lateral habenula (LHb) to counteract the protective effect of KD. Our findings uncover a gut microbiota‐brain axis mechanism for KD consumption to protect against depressive‐like behavior.

  • Open Access

    Probiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding

    by Shuo Feng, Shu-Xin Zhou, Zi-Lin Si, Yu-Min Cai, Yi-Fan Huangfu, Yi-Jia Hou, Zi-Tong Wang, Qi Liu, Hong-Xi Liu, Li-Juan Zhai, et al.

    While the impact of non-antibiotic drugs on gut bacteria is well-known, their mechanisms of action remain poorly characterized, and effective mitigation strategies for drug-induced dysbiosis are still limited. Here, we screened bacteria-derived drug-target protein homologs (BDTPHs) mapped to 63 target proteins and 107 associated drugs to quantify “drug–BDTPH–bacterium” interactions. These interactions were validated by co-culture experiments using 10 drugs and 25 strains, enzyme assays, and genetic perturbations in Escherichia coli. Ex vivo and in vivo testing with six drugs showed that over 50% of affected genera exhibited high affinity, indicating microbiota alterations through the “drug–BDTPH–bacterium” axis. Leveraging this quantitative interaction framework, we identified a strain of Bifidobacterium animalis that can competitively bind methotrexate through high-affinity BDTPH, thereby effectively alleviating gut microbiota dysbiosis in vivo. Our findings elucidate a mechanism by which non-antibiotic drug effects on bacterial growth, and suggest a universal homology-based competition strategy to restore drug-disrupted microbiota.


  • Predicting cerebral acetylcholine dynamics with huperzine A pharmacokinetics in blood via mPBPK-PD modeling

    by Jiaying Wang, Yangfan Zhang, Haoqian Wu, Siqi Yu, Xiaoying Cai, Youying Zhang, Jian Chen, Zixing Chen, Xiao Zheng, Haiping Hao


  • Open Access

    Dual cognition-improving mechanisms of huperzine A in vascular dementia mice via neurometabolic regulation

    by Yangfan Zhang, Zemin Li, Ruizhe Nie, Haoqian Wu, Jiajie Li, Xiaoying Cai, Youying Zhang, Xuan Lin, Ruiqi Duan, Shunyuan Liu, et al.

    Vascular dementia (VaD) is a poorly treated disease that involves complicated pathology such as neuronal damage and neural circuit dysfunction. Huperzine A (HupA) is commonly used for clinical treatment of cognitive impairment, the mechanism of which is prevalently attributed to the increase in synaptic acetylcholine (ACh) levels. Here we elucidate an integral neurometabolic mechanism for HupA in the treatment of cognitive impairment in VaD. HupA effectively alleviated bilateral common carotid artery occlusion (BCCAO)-induced neuronal damage, neuroinflammation, and cognitive decline in mice, accompanied by a notable restoration of ACh homeostasis in the dorsal striatum (STRd). HupA or ACh injection into the STRd recapitulated the cognitive effects, while an α7nAChR antagonist blocked the neuroprotective effects in both primary neurons and VaD mice. By neural circuit mapping and functional manipulation, we further identified that HupA-induced ACh accumulation in the STRd recruits a STRdGABA→SNrGABA neural circuit to synergistically improve the cognitive network in VaD mice. Overall, we reveal a dual mechanism orchestrated by STRd ACh signaling through which HupA confers cognitive improvement in VaD mice. These findings underscore the therapeutic value of targeting neurometabolic nodes for the treatment of VaD and potentially other forms of dementia.


  • Open Access

    Taurocholic Acid Is Associated With Disturbed Functional Connectivity in the Hippocampus of Patients With Depression

    by Xiaoying Cai, Taipeng Sun, Mengzhen Feng, Gang Chen, Junchi Zhou, Hong Zhuang, Dan Wang, Ying Chen, Zhen Cheng, Zhi Xu, et al.

    Major Depressive Disorder (MDD) is characterized by abnormal metabolic profiles along the microbiome‐gut‐brain axis. Bile acids (BAs), a class of steroid compounds regulated by the host and microbes, are increasingly shown to become dysregulated in models of depression. However, the identity of key regulatory BA metabolite in patients with MDD and associated mechanism remain to be clarified. Here, a prospective observational study in patients with depression ( n = 235) and control subjects ( n = 232) for identifying functional BA metabolites regulating depressive behavior and brain functional connectivity is performed. Using comparative metabolomics assay, an increased level of taurocholic acid (TCA) in the serum of patients with MDD is observed, which is reversed by anti‐depressant treatments. Transferring fecal microbiome from patients with MDD induced TCA accumulation to the hippocampus of recipient mice exhibiting depression‐like behavior. TCA supplementation suppressed hippocampal neurogenesis, triggered microglial activation, and elicited depression‐like behavior in mice, which are alleviated by a sphingosine‐1‐phosphate receptor 2 (S1PR2) antagonist. In patients with MDD, functional neuroimaging and spearman correlation analysis revealed that circulating TCA is strongly correlated with functional connectivity in the subregions of hippocampus. The results highlight the potential of harnessing TCA as a prognostic marker and therapeutic target for depression.


  • Tryptophan metabolites at the service of neuroimmune sensing of microbes

    by Ying Wang, Jiajie Li, Zhengqi Lian, Haiping Hao, Xiao Zheng


  • Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites

    by Yuanlong Hou, Hao Wu, Zhuangyi Zhang, Jie Wang, Qifan Chen, Chunang Lian, Dandan He, Ziguang Li, Wei Wei, Xin Lin, et al.

    Background: Late-onset diarrhoea remains a poorly managed concern for clinical irinotecan therapy. Although bacterial β-glucuronidases (β-GUS) mediated SN-38 production is prevailingly thought to mediate intestinal toxicity, β-GUS inhibitors confer limited benefits in the clinic. Objective: This study aimed to explore the role and mechanism of endogenous bacterial metabolites in susceptibility to irinotecan toxicity. Design: Gut microbiota profiles and metabolites in patients with colorectal cancer (CRC) with or without diarrhoea were investigated via 16S rRNA sequencing, shotgun metagenomics and metabolomics. The role of microbial metabolites was investigated in mice by metabolic bioengineering and intestinal organoid culture. The mechanism of microbial metabolites on intestinal stem cells was investigated by transcriptional profiling and chemical intervention. Results: Gut microbial configuration was differentially remodelled in diarrhoea and non-diarrhoea patients with irinotecan therapy, and the susceptibility was transmissible to recipient mice via transplantation of baseline faecal microbiome. Bacteroides intestinalis ( B. intestinalis ) was notably expanded in the diarrhoea-prone cohorts as well as in irinotecan-treated mice. B. intestinalis colonisation sensitised intestinal epithelia to irinotecan-induced chemical injury, partially via tryptophan metabolite indole-3-acetate (IAA). Both B. intestinalis and bioengineered bacteria that produce IAA exacerbated irinotecan-induced intestinal epithelial injury in mice. Mechanistically, IAA suppressed PI3K-Akt signalling, thereby impairing the renewal of intestinal epithelia under the insult of irinotecan. In clinical patients receiving irinotecan therapy, faecal IAA level was closely associated with the diarrhoea severity. Conclusion: Our study uncovers the mechanism of endogenous bacterial metabolite in shaping the individual susceptibility to irinotecan toxicity and suggests IAA as a potential predictive biomarker.


  • Metabolic insights into gut microbiota in the pharmacology of natural medicines

    by Zixin Chen, Junchi Zhou, Xiao Zheng, Hao Xie, Haiping Hao